FARIM – FARmakoterapie po Infarktu Myokardu (Post-Myocardial Infarction Pharmacotherapy study)

Česká verzia

Authors: J. Špinar ¹; J. Vítovec ²; L. Špinarová V Zastoupení Řešitelů Studie Farim ²
Authors place of work: Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC ¹; I. interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny v Brně, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC ²
Published in the journal: Vnitř Lék 2011; 57(9): 778-784
Category: 65th birthday Mudr. Jany Laciné and and 60th birthday Milana Tržila

Summary

A total of 2,500 patients with an anamnesis of myocardial infarction at least 1 month prior to inclusion in the study who visited a general practitioner or an internal medicine or cardiology specialist were examined. Through an internet-based portal, physicians entered patient data, their complaints, treatment, blood pressure, heart rate and main biochemical parameters. There were more men (1 787 vs. 713) and patients under 70 years of age (1 491 vs. 1 009) in the cohort. Eighteen percent of patients had more than one MI. Mean age at the first infarction was 59.2 years in men and 64.9 in women (p < 0.001). NYHA breathlessness category higher than II was reported by 13.0% of patients only, 57.2% of patients reported they never had chest pain following an MI. Hypertension was the most frequent co-morbidity (84%). The mean blood pressure was 132/79 mmHg with no difference between men and women, the mean heart rate was 68/min, the mean cholesterol level was 4.55 mmol/l. 66% of patients had been prescribed all recommended pharmacotherapeutic groups according to guidelines (RAAS blockers, beta-blockers, statins, antiaggregation agents) and each group individually was used in > 90% of patients. There were no differences between men and women and older and younger patients. ACE inhibitors and statins were not always prescribed in recommended (high) doses. Ramipril and perindopril were the most frequently prescribed ACE inhibitors and atorvastatin the most frequently prescribed statin. There was a high level of compliance when it came to achieving the target blood pressure and heart rate values as well as to prescribing of the recommended drug groups. However, renin-angiotensin system-blocking agents and statins are not being prescribed in sufficiently high doses and this should be improved.

Key words:
myocardial infarction – therapy – target values

Zdroje

1. Šimon J et al. Epidemiologie a prevence ischemické choroby srdeční. 1. vyd. Praha: Grada Publishing 2001.

2. Špinar J, Vítovec J et al. Ischemická choroba srdeční. 1. vyd. Praha: Grada Publishing 2003.

3. Widimský P, Hlinomaz O, Kala P et al. Diagnostika a léčba akutního infarktu myokardu s elevacemi ST. Cor Vasa 2009; 51: 724–740.

4. Bělohlávek J, Aschermann M. Doporučený postup pro diagnostiku a léčbu akutních koronárních syndromů bez elevací ST úseků na EKG. Vnitř Lék 2008; 54 (Suppl 1): 1S7–1S23.

5. Yusuf S, Teo K, Pogue J et al. ONTARGET study investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–1559.

6. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 2003; 349: 1893–1906.

7. Vítovec J, Špinar J, Souček M et al. Je kombinace inhibitorů ACE a blokátorů receptorů pro angiotenzin II v léčbě kardiovaskulárních onemocnění indikovaná? Remedia 2009; 19: 149–152.

8. Pepine CJ for the INVEST group. Outcomes from randomised trial of calcium antagonist and non calcium antagonist blood pressure treatment strategy in patients with coronary artery disease. JAMA 2003; 290: 2859–2861.

9. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidémií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181–197.

10. Walentin L, Becker RC, Budaj A et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057.

11. Wiviott SD, Braunwald E, McCabe CH et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015.

12. Špinar J, Ludka O, Sepši M et al v zastoupení řešitelů registru Brno. Registr BRNO 2: farmakoterapie po infarktu myokardu. Vnitř Lék 2010; 56: 533–540.

13. European cardiovascular disease statistics 2008. Brussels: European Heart Network 2008.

14. Cífková R. Co způsobuje pokles úmrtnosti na ischemickou chorobu srdeční? – editorial. Vnitř Lék 2011; 57: 435–436.

15. Mehta SR, Granger CB, Boden WE et al. TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 360: 2165–2175.

16. Van de Werf F, Bax J, Betriu A et al. ESC Committee for Practice Guidelines (GPC). Management of acute myocardial infarction in patients presenting with persistent ST--segment elevation: the task force on the management of ST-segment acute myocardial infarction of the European Society of cardiology. Eur Heart J 2008; 29: 2909–2945.

17. Groch L. Co způsobuje pokles úmrtnosti na ischemickou chorobu srdeční? – editorial. Vnitř Lék 2011; 57: 437–438.

18. Boden WE, O’Rourke RA, Teo KK et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503–1516.

19. Špinar J. Máme na to kuráž (COURAGE)? Cor et Vasa 2007; 49: K 156.

20. Kotík L. Snížení morbidity a mortality nemocných s chronickými formami ischemické choroby srdeční je výsledkem konzervativní léčby. Vnitř Lék 2011; 57: 497–501.

21. Sabatine MS, Cannon CP, Gibson CM et al. Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fybrinolytics: the PCI-CLARITY study. JAMA 2005; 294: 1224–1232.

22. Wiviott SD, Braunwald E, McCabe CH et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015.

23. Špinar J, Vítovec J. Komu zvoní hrana. Kardiol Rev 2009; 11: 197–199.

24. Borer JS. Heart rate: from risk marker to risk factor. Eur Heart J 2008; 10 (Suppl): F2–F6.

25. Bangalore S, Messerli FH, Ou F et al. CRUSADE Investigators. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J 2010; 31: 552–560.

26. Yusuf S, Sleight P, Pogue J et al. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.

27. Fox KM. EURopean Trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.

28. Braunwald E, Domanski MJ, Fowler SE et al. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–2068.

29. Pedersen TR, Faergeman O, Kastelein JJ et al. Incremental Decrease in End Points Through Aggressive Lipid-Lowering Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2006; 294: 2437–2445.

30. Špinar J, Ludka O, Šenkyříková M et al. Hladiny cholesterolu v závislosti na věku. Vnitř Lék 2009; 55: 724–729.

31. Hradec J. Máme léčit nemocné se srdečním selháním statiny? Výsledky klinické studie CORONA. Remedia 2008; 8: 176–179.

32. Vítovec J, Špinarová L, Špinar J. Sekundární prevence po infarktu myokardu – režimové a farmakologické postupy. Intern med pro prax 2001; 5: 202–204.

33. Kotseva K, Wood D, De Backer G et al. EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929–940.

34. Mayer jr. O, Šimon J, Galovcová M et al. Úroveň sekundární prevence ischemické choroby srdeční u českách pacienců ve studii EUROASPIRE III. Cor Vasa 2008; 50: 156–162.